Twenty-two newbie managers, fresh from B-schools across India, are raring to go. Only, they won’t make spreadsheets to sell soaps or fizzy drinks. From June, they will assist senior bureaucrats across 11 districts of Jharkhand where the Centre is funding uplift schemes. These managers — from IIT-Kharagpur, Tata Institute of Social Sciences (TISS)-Mumbai, Visva-Bharti in Bengal’s Santiniketan, XISS-Ranchi, XLRI-Jamshedpur and others — are Prime Minister’s Rural Development Fellows in some of...
More »SEARCH RESULT
Total Matching Records found : 5846
For a fair deal -Kirti Singh
The amendment to the Marriage Laws Bill needs to be redrafted to ensure, among other things, greater economic rights for divorced women. SINCE the 1950s, successive amendments to different personal laws on marriage and divorce have mainly focussed on enlarging the grounds for divorce. In the 1960s and 1970s, cruelty and desertion and thereafter mutual consent were added as grounds for divorce in the Hindu Marriage Act (HMA) and the...
More »Fetters on the media? -V Venkatesan
The proposal made by a Supreme Court Bench to have guidelines for legal reporting is seen as a serious threat to the freedom of the media. Paradoxes are not new to India. But the current challenges to the freedom of expression and the freedom of the media are sure to confound a future historian looking for explanations. The country is fortunate to have the best of historical circumstances that are conducive...
More »Blind to realities-TK Rajalakshmi
The proposed criminalisation of consensual sex between youngsters in the 16-18 age group is seen as regressive and in denial of social realities. THE minimum age for consensual sex has been raised from 16 to 18 in the amended Protection of Children from Sexual Offences Bill, 2011, recently approved by the Union Cabinet. If approved by Parliament, this will make sexual activity with a person below 18 a criminal offence,...
More »Protests in US over high pricing of Novartis' anti-cancer drug Glivec-Divya Rajagopal
Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs. Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments...
More »
